Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.
最新の財務諸表(Form-10K)によると、Alps Group Incの総資産は$3で、純損失は$0です。
GLLIRの主要な財務比率は何ですか?
Alps Group Incの流動比率は0.27、純利益率は0、1株当たり売上高は$0です。
Alps Group Incの収益はセグメントまたは地域別にどのように分けられていますか?
Alps Group Inc の最大収益セグメントは Banking and Related Activities で、最新の利益発表における収益は 308,627,000 です。地域別に見ると、United States が Alps Group Inc の主要市場であり、収益は 308,627,000 です。